Home · Health · Sep 11 archive
How Did a Heart Drug With So Much Promise Fall So Flat?
Confirmed
In Short: Experts warn of the risks of early access to experimental drugs, highlighting the case of retatrutide, which has led to safety concerns and regulatory headaches.
Experts have told the BBC that this is one of the first times they have seen copycat versions of an experimental drug, still in the throes of being tested, become so widely available. This has raised significant concerns about the safety and efficacy of the drug, especially as it has shown early promise in clinical trials.
Tom, a participant in the trial, accidentally took eight times the recommended dose of a fake version of retatrutide and nearly ended up in the hospital, illustrating the potential dangers of early access to experimental drugs.
The high rate of failure for drugs in the Phase III stage of testing is primarily due to drugs not working as well in large, diverse human populations as they do in smaller early tests, or because they reveal unexpected safety hazards. This has led to a headache not only for Eli Lilly, the pharmaceutical company behind retatrutide, but for regulators in the UK and around the world.
Only 50% of drugs in this Phase III stage of testing in the US are eventually approved by the FDA, so there is no guarantee that retatrutide will ever hit the market. The drug's journey from promise to potential failure highlights the challenges of drug development and the importance of rigorous testing.
What's confirmed
- Experts have told the BBC that this is one of the first times they have seen copycat versions of an experimental drug, still in the throes of being tested, become so widely available. This has raised significant concerns about the safety and efficacy of the drug, especially as it has shown early promise in clinical trials.
- Tom, a participant in the trial, accidentally took eight times the recommended dose of a fake version of retatrutide and nearly ended up in the hospital, illustrating the potential dangers of early access to experimental drugs.
- The high rate of failure for drugs in the Phase III stage of testing is primarily due to drugs not working as well in large, diverse human populations as they do in smaller early tests, or because they reveal unexpected safety hazards. This has led to a headache not only for Eli Lilly, the pharmaceutical company behind retatrutide, but for regulators in the UK and around the world.
- Only 50% of drugs in this Phase III stage of testing in the US are eventually approved by the FDA, so there is no guarantee that retatrutide will ever hit the market. The drug's journey from promise to potential failure highlights the challenges of drug development and the importance of rigorous testing.
What's still developing
- He says trial participants need to meet strict criteria before they are given the green light to start taking the real drug or a placebo.
- Test your knowledge with our new weekday mini crossword By Matthew Herper, Jason Mast, and Angus Chen Matthew Herper covers medical innovation — both its promise and its perils.
- Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community.
- At an off-site leadership meeting held by Moderna in March 2023 — after mid-stage results of the biotech company’s cancer vaccine showed promise — CEO Stéphane Bancel had the floor.